

EID R&D MATRIX

		Basic research	Drugs	Vaccines	Biologics	Diagnostics	Vector control products
Arenaviral haemorrhagic fevers	Lassa fever	✓	✓	✓	✓	✓	-
	Other arenaviral R&D in combination with Lassa fever	✓	✓	✓	✓	✓	-
	Arenaviral haemorrhagic fevers other than Lassa fever	✓	✓	✓	✓	✓	-
Bunyaviral diseases	Crimean-Congo Haemorrhagic Fever (CCHF)	✓	✓	✓	✓	✓	✓
	Rift Valley Fever (RVF)	✓	✓	✓	✓	✓	✓
	Severe Fever with Thrombocytopenia Syndrome (SFTS)	✓	✓	✓	✓	✓	✓
	Other bunyaviral R&D in combination with CCHF and/or RVF	✓	✓	✓	✓	✓	✓
	Bunyaviral diseases other than CCHF, RVF and SFTS	✓	✓	✓	✓	✓	✓
Chikungunya		✓	✓	✓	✓	✓	✓
Coronaviral diseases	Middle East Respiratory Syndrome (MERS)	✓	✓	✓	✓	✓	✓
	Severe Acute Respiratory Syndrome (SARS)	✓	✓	✓	✓	✓	✓
	Coronavirus disease 2019 (COVID-19)#	✓	✓	✓	✓	✓	✓
	Other coronaviral R&D in combination with MERS and/or SARS and/or COVID-19	✓	✓	✓	✓	✓	-
	Highly pathogenic coronaviral diseases other than MERS, SARS and COVID-19	✓	✓	✓	✓	✓	-
Emergent non-polio enteroviruses (including EV71, D68)		✓	✓	✓	✓	✓	-
Filoviral diseases	Ebola	✓	✓	✓	✓	✓	✓
	Marburg	✓	✓	✓	✓	✓	✓
	Other filoviral R&D in combination with Ebola and/or Marburg	✓	✓	✓	✓	✓	-
	Filoviral diseases other than Ebola and Marburg	✓	✓	✓	✓	✓	✓
Henipaviral diseases	Nipah	✓	✓	✓	✓	✓	✓
	Other henipaviral R&D including in combination with Nipah	✓	✓	✓	✓	✓	-
	Henipaviral diseases other than Nipah	✓	✓	✓	✓	✓	✓
Zika		✓	✓	✓	✓	✓	✓
Investment applicable to more than one emerging infectious disease*							
Broad-spectrum antivirals		Fundamental research		Therapeutic platforms		Vaccine platforms	
✓		✓		✓		✓	
Other investment applicable to more than one emerging infectious disease or to more than one global health area*							
Platform Technologies				Multi-disease vector control		Core funding of a multi-disease R&D organisation	
General diagnostic platforms	Adjuvants & immunomodulators	Drug delivery technologies & devices	Vaccine delivery technologies & devices				
✓	✓	✓	✓	✓		✓	

✓denotes a category where a disease or product is included in the survey

For COVID-19 only, we are selectively expanding our scope to include R&D for devices and ventilators that has been conducted explicitly in the context of COVID-19 and in response to the pandemic. This R&D is captured under 'Unspecified product'.

* The G-FINDER project covers three global health areas: neglected diseases, emerging infectious diseases, and sexual & reproductive health issues.